Genotypic and Phenotypic Cross-Drug Resistance of Harboring Drug-Resistant HIV Type 1 Subtype B′ Strains from Former Blood Donors in Central Chinese Provinces

Abstract

The objective of this study was to assess the patterns of genotypic and phenotypic resistance in a population of blood donor patients infected with HIV-1 subtype B′ (Thai B′, a clade of HIV-1 B) from central China, previously treated and harboring NRTI and NNRTI resistance mutations, with the purpose of designing effective therapeutic regimens. The HIV-1 pol genes from 65 patients were sequenced and estimated for drug resistance while the viruses isolated from the patients were used to analyze the phenotype based on the TZM-bl cell line. All the HIV-1 strains harboring one or more drug resistance mutations to HIV-1 RTIs possessed high cross-resistance to EFV (100%) and DLV (92%), as well as to ABC (84%) and TDF (77%), which are much higher than both FTC and 3TC (42%). There were more thymidine analog mutation (TAM)-associated mutations in the AZT/ddI/NVP group (62.5%) than in the d4T/ddI/NVP group (32.65%). A phenotypic assay showed high concordance between genotypic and phenotypic cross-resistance. This study showed there was a high level of cross-drug resistance to HIV-1 RTIs among Chinese AIDS patients harboring resistant strains, and there is also a high prevalence of primary resistance to 3TC, suggesting that one important recommendation should be the realization of genotypes in all naive patients due to the high prevalence of NRTI and NNRTI mutations.

Get full access to this article

View all access options for this article.

References

, Liu

, Detels

. HIV-1 infection in commercial plasma donors in China. Lancet, 1995; 346:61–62.

, Detels

. The HIV epidemic in China: History, response, and challenge. Cell Res, 2005; 15:825–832.

Zhang

, Dou

, Yu

et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis, 2008; 47:825–833.

hao

. AIDS epidemic at age 25 and control efforts in China. Retrovirology, 2006; 3:87.

DeGruttola

, Dix

, D'Aquila

et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther, 2000; 5:41–48.

Haubrich

, Demeter

. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: Retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr, 2001; 26,Suppl 1:S51–59.

, Li

et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res, 2005; 15:843–849.

Zhang

, Han

, Cui

et al. The impact of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Jpn J Infect Dis, 2008; 61:361–365.

Peeters

, Liegeois

, Torimiro

et al. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J Virol, 1999; 73:7368–7375.

10.

Platt

, Wehrly

, Kuhmann

et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of human immunodeficiency virus type 1. J Virol, 1998; 72:2855–2864.

11.

, Sun

, Xing

et al. Genotype and phenotype patterns of drug-resistant HIV-1 subtype B' (Thai B) isolated from patients failing antiretroviral therapy in China. J Acquir Immune Defic Syndr, 2007; 44:14–19.

12.

Bulgheroni

, Croce

, Citterio

et al. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. J Clin Virol, 2004; 29:27–32.

13.

Minuesa

, Volk

, Gorboulev

et al. Identification of lamivudine (3TC) as a novel substrate for human organic cation transporters 1, 2 and 3. Antiviral Ther, 2008; 13:A59(Abstract No. 54).

14.

armati

, Nicastri

, Parisi

et al. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. J Clin Microbiol, 2002; 40:335–340.

15.

Hanna

, D'Aquila

. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis, 2001; 32:774–782.

16.

Kumar

, Nei

, Dudley

et al. MEGA: A biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform, 2008; 9:299–306.

17.

Johnson

, Brun-Vezinet

, Clotet

et al. Update of the drug resistance mutations in HIV-1. Top HIV Med, 2008; 16:138–145.

18.

, Guo

, Yuan

et al. Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang province of China. Retrovirology, 2009; 6:45.

19.

Shafer

, Schapiro

. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev, 2008; 10,2:67–84.

20.

DHHS: Guidelines for the Use of Antiretroviral Agents in HIV-1–Infected Adults and Adolescents. http://aidsinfor.nih.gov. 2006 May 18.

21.

Wools-Kaloustian

, Kimaiyo

, Diero

et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: Experience from western Kenya. AIDS, 2006; 20:41–48.

22.

Geretti

. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis, 2007; 20:22–32.

23.

Droz

, Morand-Joubert

, Raguin

. Impact and evolution of resistance in patients treated by a salvage regimen combining amprenavir, lopinavir and ritonavir (the puzzle 1 study) Antiviral Ther, 2002; 7:S111.